

LS

2739 - 7356

The Pharmacology of Sleep

Contributors

J. Adrien, F. Albani, A. Baruzzi, M. Berger, E.O. Bixler
A.A. Borbély, D.G. Dikeos, R. Drucker-Colín, R. Fritsch Montero
Y. Hishikawa, S. Inoué, A. Kales, E. Lugaresi, H. Merchant-Nancy
J.M. Monti, W.E. Müller, O. Pompeiano, M. Radulovacki
A.E. Reinberg, D. Riemann, R. Riva, E. Sforza, C.R. Soldatos
G. Tononi, E. Van Cauter, A. Vela-Bueno, A.N. Vgontzas
A. Wauquier

Editor

Anthony Kales



Springer

2 F.

Contents

CHAPTER 1

Evolution of Concepts of Mechanisms of Sleep

R. DRUCKER-COLÍN and H. MERCHANT-NANCY	1
A. Introduction	1
B. Brief Historical Overview	1
C. Early Neurophysiological Concepts of Sleep (From Passive to Active)	2
D. Neurohumoral Concepts of Sleep Regulation	6
I. Progressive Development of an Old Idea	6
II. Sleep Factor Regulation Viewed Physiologically	11
E. Neurochemical – Neurophysiological Concepts of Sleep Regulation	12
I. Classical Neurotransmitters	12
II. Neurotransmitters and Single-Unit Studies	16
F. Final Considerations	19
G. Summary	21
References	21

CHAPTER 2

Principles of Sleep Regulation: Implications for the Effect of Hypnotics on Sleep

A.A. BORBÉLY. With 6 Figures	29
A. Basic Processes	29
B. Sleep Homeostasis	29
I. EEG Slow Waves as Indicators of “Sleep Pressure”	29
1. Global Changes During Baseline Sleep Episodes	31
2. Effect of Sleep Deprivation	31
II. Ultradian Dynamics of Slow-Wave Activity and Spindle Activity	33
1. Baseline Sleep and Recovery Sleep After Sleep Deprivation	33

2. Neurophysiological Basis of Slow Waves and Sleep Spindles	33
III. Homeostasis of REM Sleep and Interactions with Non-REM Sleep	34
C. Effect of Hypnotics on Sleep and the Sleep EEG	35
I. Benzodiazepine Hypnotics Alter the Sleep EEG	35
II. Benzodiazepine-Receptor Agonists Have Similar Effects on the Sleep EEG	37
III. Do Hypnotics Disrupt Sleep Homeostasis?	37
IV. Effect of Benzodiazepine Hypnotics on Circadian Rhythms	40
D. Concluding Remarks: Pitfalls in Pharmacological Sleep Studies	40
E. Summary	41
References	42

CHAPTER 3

Principles of Chronopharmacology and the Sleep-Wake Rhythm

A.E. REINBERG. With 2 Figures	47
A. Introduction	47
B. Properties of Biological Rhythms	50
C. Biological Rhythms as Adaptive Phenomena to Predictable Changes in Environmental Factors	51
D. Temporal Distribution and Dosing Time of Therapies	51
E. Concepts in Chronopharmacology	52
I. Chronopharmacokinetics (or Chronokinetics) of a Drug	52
II. Biomechanisms Presumably Involved in Chronokinetic Changes	53
III. Chronesthesia of a Biosystem	54
IV. Chronergy of a Chemical Agent	55
V. Chronotherapy	56
F. Drug Effects on Sleep, Anesthesia and Related Processes	56
I. Anesthetics	56
II. Ethanol	57
III. Drug-Induced Drowsiness	57
G. Shift Workers, Jet Lag and Sleeping Pills	58
I. Shift Workers and Sleeping Pills	58
II. Jet Lag, Sleeping Pills, Melatonin and Bright Light	59
H. Summary	60
References	60

CHAPTER 4

Pharmacology of the Catecholaminergic System

A. WAUQUIER	65
A. Introduction	65
B. Amine-Depleting and Synthesis-Inhibiting Substances	66
I. Catecholaminergic-Depleting Substances: Reserpine	66
II. Dopamine- β -hydroxylase Inhibitors	68
III. Tyrosine Hydroxylase Inhibitor	69
IV. Norepinephrine Uptake Blockers	69
V. In Conclusion	70
C. Adrenergic Agonists and Antagonists	70
I. α_1 -Antagonists (Phenoxybenzamine, Prazosin)	70
II. α_1 -Agonist	74
III. α_2 -Antagonists (Phentolamine, Yohimbine)	74
IV. α_2 -Agonist	75
V. β -Adrenergic Antagonists	75
VI. β -Adrenergic Agonists	76
VII. In Conclusion	76
D. Dopamine Agonists and Antagonists	77
I. Dopamine ₂ -Agonists	80
II. Dopamine ₂ -Antagonists	80
III. Dopamine ₁ -Antagonists	82
IV. In Conclusion	83
E. Differential Regulation of Waking and PS by Catecholamines	83
F. Summary	84
References	85

CHAPTER 5

The Serotonergic System and Sleep-Wakefulness Regulation

J. ADRIEN. With 5 Figures	91
A. The Serotonergic System	91
I. Serotonergic Nuclei and Pathways	91
II. Serotonergic Metabolism and Neurotransmission	93
1. Synthesis of Serotonin	93
2. Release and Inactivation of Serotonin	93
3. Impairment of the Synthesis, Release and Catabolism of Serotonin	93
III. Serotonergic Receptors	94
1. 5-HT _{1A} Receptors	95
2. 5-HT ₂ Receptors	95

3. 5-HT ₃ Receptors	95
4. 5-HT ₄ Receptors	95
IV. Conclusion	95
B. Serotonin and Sleep	96
I. Spontaneous Activity of the Serotonergic System During Sleep and Wakefulness	96
II. Pharmacological Impairment of Serotonergic Neurotransmission	97
1. Enhancement of Serotonin Levels in the Brain	97
2. Decrease in Serotonin Levels in the Brain	100
III. Pharmacological Impairment of Receptor Function	103
1. 5-HT _{1A} Receptors	103
2. 5-HT _{1B} and 5-HT _{1C} Receptors	105
3. 5-HT ₂ Receptors	105
4. 5-HT ₃ Receptors	107
5. Interaction Between the Various Serotonergic Receptor Types	108
IV. How Is Serotonin Involved in Sleep-Wakefulness Regulation?	109
C. Summary	109
References	111

CHAPTER 6

Pharmacology of the Histaminergic System

J.M. MONTI	117
A. Introduction	117
B. Histamine Synthesis and Metabolism	117
C. Histaminergic Nuclei and Pathways	119
D. Histamine Receptors	122
E. Effects of Histamine at the Cellular Level	124
F. Drugs Acting at the Histamine Receptors	125
I. H ₁ Receptor	125
II. H ₂ Receptor	126
III. H ₃ Receptor	126
G. Histamine Control of the Waking State	126
I. Electrophysiological Studies	127
II. Circadian Rhythms	127
III. Lesion Studies	127
IV. Pharmacological Studies	128
1. Intracerebroventricular Administration of Histamine	128
2. Histamine Synthesis Inhibition	130
3. H ₁ Receptor Agonists and Antagonists	130

4. H ₂ Receptor Agonists and Antagonists	132
5. H ₃ Receptor Agonists and Antagonists	133
H. Summary	134
References	135

CHAPTER 7

Pharmacology of the Cholinergic System

G. TONONI and O. POMPEIANO	143
A. Introduction	143
B. Biochemistry, Anatomy, and Physiology of the Cholinergic System	143
I. Biochemistry	143
1. Synthesis	143
2. Storage and Release	144
II. Anatomy	145
1. Cholinergic Cells	145
2. Basal Forebrain Cholinergic Groups	146
3. Brain Stem Cholinergic Groups	147
III. Cholinergic Receptors	148
1. Nicotinic Receptors	148
2. Muscarinic Receptors	149
IV. Postsynaptic Effects	149
C. Cholinergic System and Sleep	151
I. Spontaneous Activity of Cholinergic Neurons	151
1. Nucleus Basalis	151
2. LDT/PPT	151
II. Spontaneous Release of ACh	152
III. Availability of Cholinergic Receptors and AChE	153
IV. Lesions of the Cholinergic System	154
1. Lesions and Stimulation of Basal Forebrain	154
2. Lesions of LDT/PPT	154
V. Pharmacological Manipulations of the Cholinergic System	155
1. Cortical Activation	155
2. Hippocampal Theta Rhythm	156
3. REM Sleep	157
4. ACh and Atonia	163
5. ACh and PGO Waves	164
6. Diseases Involving ACh and Sleep	164
D. Cholinergic System and Postural Mechanisms	166
I. Effects on Decerebrate Rigidity	166
II. Effects on Vestibulospinal Reflexes	169

III. Effects on Postural Adjustments	
During Cortically Induced Movements	173
IV. Cerebellar Regulation of Vestibular Reflexes	175
E. Cholinergic System and Respiratory Mechanisms	181
F. Conclusions	184
I. Cholinergic System and Cortical Activation	184
II. Cholinergic System and REM Sleep	186
III. Cholinergic System and Postural Mechanisms	187
G. Summary	189
References	190

CHAPTER 8

Pharmacology of the GABAergic/Benzodiazepine System

W.E. MÜLLER. With 12 Figures	211
A. Introduction	211
B. Functional Evidence for the GABA-mimetic Properties of Benzodiazepines	214
I. Electrophysiology	216
II. Pharmacology and Biochemistry	216
III. Histochemistry	216
IV. Receptor Interactions: Effects of GABA Receptor-Agonists on Benzodiazepine-Receptor Binding and Vice Versa	218
C. GABA _A Receptor – Benzodiazepine Receptor – Chloride Channel Complex	218
I. Functional Aspects	218
II. Structural Aspects	220
III. Chain of Events from Benzodiazepine-Receptor Occupation to Pharmacological Response	221
IV. Benzodiazepine-Receptor Ligands with Different Intrinsic Activities: Concept of Agonists, Antagonists, and Inverse Agonists	223
V. Receptor Subclassess and Hypnotic Benzodiazepines	225
VI. Relationship Between Benzodiazepine-Receptor Affinity and Biological Activity	226
D. Specific Hypnotic Drugs	234
I. Benzodiazepines	234
II. Barbiturates	235
III. Zopiclone and Zolpidem	236
E. Summary	236
References	237

CHAPTER 9

Pharmacology of the CNS Peptides

S. INOUÉ. With 2 Figures	243
A. Introduction	243
B. Delta-Sleep-Inducing Peptide: A Circadian Programmer?	244
I. Research Background	244
II. Distribution and Biosynthesis in the Brain	245
III. Circadian Sleep-Waking Rhythm	245
IV. Sleep-Promoting Activity of Structural Analogs	246
V. Aspects of "Extra-Sleep" Activities and Neurotransmitter Systems	246
1. Antinociceptive Activity and Sleep	246
2. Thermoregulation	247
VI. Concluding Remarks	247
C. Glutathione: A Neuronal Detoxification Factor?	247
I. Research Background	247
II. Sleep-Modulatory Activity of Oxidized Glutathione	248
1. Bioassay	248
2. Effects on Sleep	248
3. Effects on Brain Temperature	249
III. Sleep-Modulatory Activity of Reduced Glutathione	249
IV. Possible Mechanisms	251
D. Muramyl Peptides and Cytokines: Somnopyrogenic Immunomodulators?	252
I. Research Background	252
II. Muramyl Peptides and Infectious Diseases	253
1. Bacterial and Viral Infections and Sleep	253
2. Cerebral Site of Action	254
III. Interleukin-1	254
1. Somnopyrogenic Activities	254
2. Transport	255
3. IL-1 Receptors	255
4. Interactions with Other Sleep Substances	256
IV. Tumor Necrosis Factor	256
V. Interferon	257
VI. Integrative Remarks	257
E. Hypothalamo-hypophyseal Hormones: Neuroendocrine Transducers?	257
I. Research Background	257
II. Growth Hormone-Related Hormones	258
III. Corticotropin-Related Hormones	259
IV. Thyrotropin-Related Hormones	259

V. Prolactin	259
VI. Concluding Remarks	260
F. Satiety-Related Substances: Ischymetric Factors or Postprandial Somnogens?	260
I. Research Background	260
II. Cholecystokinin	260
III. Bombesin	261
IV. Acidic Fibroblast Growth Factor	261
V. Concluding Remarks	261
G. Vasoactive Intestinal Polypeptide and Vasopressin: Circadian Timekeepers or REM Sleep Factors?	262
H. Vasotocin: A Brain Maturation Modulator?	262
I. General Concluding Remarks	263
J. Summary	264
References	265

CHAPTER 10

Hormones and Sleep

E. VAN CAUTER. With 10 Figures	279
A. Introduction	279
B. Interactions Between Sleep, Circadian Rhythmicity and Hormonal Release	279
C. Methodology of Studies of Sleep and Hormonal Secretion	283
I. Design of Experimental Protocols	283
II. Analysis of Hormonal Data	284
III. Analysis of the Interaction Between Sleep and Hormonal Release	285
D. Modulation of Hormonal Release by Sleep and Wake	287
I. Corticotropic Axis	287
II. Somatotropic Axis	289
III. Thyrotropic Axis	292
IV. Lactotropic Axis	293
V. Gonadotropic Axis	296
VI. Glucose Tolerance and Insulin Secretion	296
VII. Hormones Regulating Water Balance	297
E. Sleep-Promoting Effects of Hormones	300
I. Growth Hormone-Releasing Hormone and Growth Hormone	300
II. Melatonin	300
F. Conclusions	301
G. Summary	301
References	302

CHAPTER 11

Pharmacology of the Adenosine System

M. RADULOVACKI. With 2 Figures	307
A. Introduction	307
B. Effects of Adenosine and Adenosine-Related Compounds on Sleep	309
I. Intracerebroventricular Administration of Adenosine and Sleep in Rats	309
II. Microinjections of Adenosine to Preoptic Area and Sleep in Rats	310
III. Inhibition of Adenosine Deaminase and Sleep	311
IV. Adenosine Analogs and Sleep	311
C. Adenosine A ₁ Receptors in Sleep and Waking	312
I. Central A ₁ Receptor Variation During the Circadian Period	312
II. Central A ₁ Receptors in Young and Old Rats	313
III. Central A ₁ Receptors in REM Sleep Deprivation	313
D. Methylxanthines and Sleep: Effects of Blockade of Adenosine A ₁ and/or Adenosine A ₂ Receptors	314
I. Caffeine and Adenosine Agonists: Behavioral Interaction ..	314
II. Dose-Response Effects of Caffeine on Sleep	314
III. Caffeine Blocks Both Adenosine A ₁ and A ₂ Receptors: Is the Blockade of A ₁ Receptors More Important for CNS Stimulation?	315
E. Benzodiazepines and Central Adenosine Receptors	315
I. Diazepam and Adenosine Receptors in Specific Brain Areas in Rats	316
II. Triazolam and Central Adenosine Receptors	316
III. Inhibition of Adenosine Transport and Central Adenosine Receptors	317
F. Hypothesis for Adenosine Hypnotic Action	317
G. Conclusions	318
H. Summary	318
References	319

CHAPTER 12

Methodological Issues in Pharmacological Studies of Sleep

E.O. BIXLER, A.N. VGONTZAS, and A. KALES	323
A. Introduction	323
B. Objectives of the Phases of Investigation of a New Hypnotic	323
C. Methods of Measurement	324
I. Pharmacokinetic	324

II. Efficacy	325
1. Objective Measures	325
2. Subjective Estimates	326
III. Safety	327
1. Objective Measures	327
2. Patient Reports	327
D. Design and Analysis Considerations	327
I. Phase I Studies	327
II. Phase II Studies	328
1. Design of Phase II Studies	328
2. General Issues: Sleep Laboratory Studies	333
3. General Issues: Clinical Trials	334
4. General Issues: Studies of Effects on Daytime Performance	335
III. Phase III Studies	336
IV. Phase IV Studies	336
E. Summary	339
References	340

CHAPTER 13

Hypnotic Drugs

A. KALES, A.N. VGONTZAS, and E.O. BIXLER. With 2 Figures	345
A. Introduction	345
B. The Condition of Insomnia	345
I. Treatment of Insomnia	346
C. Development of Benzodiazepines and Other Hypnotic Drugs	346
I. Evaluation of Hypnotic Drugs	348
D. 1,4-Benzodiazepines with Slow Elimination and Low Binding Affinity	349
I. Flurazepam	349
1. Efficacy	349
2. Withdrawal Effects	351
3. Side Effects	353
II. Quazepam	353
1. Efficacy	353
2. Withdrawal Effects	354
3. Side Effects	354
E. 1,4-Benzodiazepines with Intermediate to Slow Elimination and Moderate Binding Affinity	354
I. Nitrazepam	354
1. Efficacy	354

2. Withdrawal Effects	355
3. Side Effects	355
F. 1,4-Benzodiazepines with Rapid to Intermediate Elimination and Low Binding Affinity	355
I. Temazepam	355
1. Efficacy	355
2. Withdrawal Effects	356
3. Side Effects	357
G. 1,4-Benzodiazepines with Rapid to Intermediate Elimination and Moderate to High Binding Affinity	358
I. Flunitrazepam	358
1. Efficacy	358
2. Withdrawal Effects	358
3. Side Effects	359
II. Loprazolam	359
1. Efficacy	359
2. Withdrawal Effects	359
3. Side Effects	359
III. Lormetazepam	360
1. Efficacy	360
2. Withdrawal Effects	360
3. Side Effects	361
H. 1,4-Benzodiazepines with Rapid Elimination and High Binding Affinity	361
I. Midazolam	361
1. Efficacy	361
2. Withdrawal Effects	362
3. Side Effects	362
I. Triazolobenzodiazepines	362
I. Brotizolam	362
1. Efficacy	362
2. Withdrawal Effects	363
3. Side Effects	363
II. Estazolam	363
1. Efficacy	363
2. Withdrawal Effects	364
3. Side Effects	364
III. Triazolam	364
1. Efficacy	364
2. Withdrawal Effects	366
3. Side Effects	367
J. New Non-Benzodiazepine Hypnotics	368
I. Zopiclone	368
1. Efficacy	368

2. Withdrawal Effects	369
3. Side Effects	370
II. Zolpidem	370
1. Efficacy	370
2. Withdrawal Effects	370
3. Side Effects	371
K. Conclusions on Efficacy of Hypnotic Drugs	371
L. Conclusions on Underlying Mechanisms for Adverse Events	372
I. Pharmacokinetic Factors	372
II. Pharmacodynamic Factors	373
III. Special Properties Related to Chemical Structure	373
M. Comments on Drug-Induced Sleep Stage Alterations	374
N. Summary	375
References	377

CHAPTER 14

Anxiolytic Drugs

A. VELA-BUENO. With 2 Figures	387
A. Introduction	387
B. Anxiolytic Drugs and Sleep: Overview	388
C. Benzodiazepines	389
I. 1,4-Benzodiazepines with Slow Elimination and Low Binding Affinity	390
1. Ketazolam	390
2. Chlordiazepoxide	390
3. Clorazepate	391
4. Fosazepam	392
II. 1,4-Benzodiazepines with Intermediate to Slow Elimination and Moderate to High Binding Affinity	392
1. Clonazepam	392
2. Diazepam	394
III. 1,4-Benzodiazepines with Rapid to Intermediate Elimination and Low Binding Affinity	395
1. Oxazepam	395
IV. 1,4-Benzodiazepines with Rapid to Intermediate Elimination and Moderate to High Binding Affinity	396
1. Lorazepam	396
V. Triazolobenzodiazepines	398
1. Alprazolam	398

2. Adinazolam	399
D. Non-Benzodiazepines, GABA _A Agonists	400
I. Cyclopyrrolones	400
1. Suriclone	400
II. Imidazopyridines	401
1. Alpidem	401
E. β -Adrenoceptor Antagonists	402
I. β -Blockers with High Lipophilicity	402
1. Propranolol	402
II. β -Blockers with Moderate Lipophilicity	403
1. Metoprolol	403
2. Pindolol	404
III. β -Blockers with Low Lipophilicity	405
1. Acebutolol	405
2. Atenolol	405
3. Nadolol	406
4. Sotalol	407
F. α_2 -Receptor-Agonists	407
I. Clonidine	407
1. Efficacy	407
2. Withdrawal Effects	408
3. Side Effects	408
II. Guanfacine	408
1. Efficacy	408
2. Withdrawal Effects	408
3. Side Effects	409
G. Serotonin Receptor-Agonists	409
I. Buspirone	409
1. Efficacy	409
2. Withdrawal Effects	410
3. Side Effects	410
H. Serotonin Receptor-Antagonists	410
I. Ritanserin	410
1. Efficacy	411
2. Withdrawal Effects	412
3. Side Effects	413
I. Summary	413
References	414

CHAPTER 15

Stimulant Drugs

Y. HISHIKAWA. With 8 Figures	421
A. Early Use of Plant Preparations Containing Central Stimulants ..	421
B. Indications for Medical Use of Central Stimulant Drugs	422
C. Clinical Features of Narcolepsy and Other Hypersomniac Conditions	423
I. Narcolepsy	423
II. Idiopathic Hypersomnia	424
III. Recurrent Hypersomnia	425
D. Central Stimulants	426
I. Caffeine	426
II. Ephedrine	427
III. Amphetamine and Methamphetamine	427
IV. Methylphenidate	429
V. Pemoline	430
VI. Mazindol	431
VII. Modafinil	432
E. Treatment of Narcolepsy and Other Hypersomniac Conditions with Central Stimulants and Other Adjunctive Drugs	433
I. Narcolepsy	433
II. Idiopathic Hypersomnia	436
III. Recurrent Hypersomnia	437
F. Other Problems Related to the Use of Central Stimulant Drugs ..	437
G. Summary	438
References	439

CHAPTER 16

Neuroleptics, Antihistamines and Antiparkinsonian Drugs:**Effects on Sleep**

C.R. SOLDATOS and D.G. DIKEOS	443
A. Introduction	443
B. Neuroleptics	443
I. Introduction	443
II. Phenothiazines	444
1. Chlorpromazine	444
2. Other Phenothiazines	446
III. Butyrophenones	447
IV. Nonclassical Neuroleptics	448
1. Sulpiride	448
2. Clozapine	448

3. Remoxipride	449
4. Ritanserin	449
V. Clinical Implications	450
C. Antihistamines	450
I. Introduction	450
II. Sedative Antihistamines	451
III. Nonsedative Antihistamines	452
IV. Clinical Implications	453
D. Antiparkinsonian Drugs	453
I. Introduction	453
II. Dopaminergic Antiparkinsonian Drugs	454
III. Anticholinergic Antiparkinsonian Drugs	454
IV. Clinical Implications	455
E. Summary	456
References	456

CHAPTER 17

Antidepressant and Antimanic Drugs

R. FRITSCH MONTERO, D. RIEMANN, and M. BERGER. With 2 Figures	465
A. Introduction	465
B. The Antidepressant Drugs	466
I. Mechanisms of Action	466
II. Classification	466
1. Sedative and Nonsedative Antidepressants	467
2. Effects on Norepinephrine, Dopamine and Serotonin ...	467
III. An Integrative Model for Depression	468
IV. Sleep and Depression	470
V. Effects of Antidepressants on Sleep	471
1. Effects of Antidepressants on REM Sleep	472
2. Effects of Antidepressants on Other Sleep Stages	480
VI. Use of Antidepressants in Sleep-Related Disorders	481
1. Psychophysiological Insomnia	481
2. Sleep Apnea Syndrome	482
3. Narcolepsy	482
C. Antimanic Drugs	482
I. Lithium	483
II. Carbamazepine	484
D. Summary	484
References	485

CHAPTER 18

Anticonvulsant Drugs

A. BARUZZI, F. ALBANI, R. RIVA, E. SFORZA, and E. LUGARESI	491
A. Introduction	491
B. Drug Reviews	493
I. Phenobarbital	493
II. Phenytoin	494
III. Carbamazepine	496
IV. Valproate	498
V. Ethosuximide	499
C. Summary	499
References	500

CHAPTER 19

Mechanisms of Benzodiazepine Drug Dependence

A.N. VGONTZAS and A. KALES. With 3 Figures	503
A. Introduction	503
B. Prevalence of Benzodiazepine Dependence	505
C. Description of Benzodiazepine-Withdrawal Symptoms	506
I. Most Frequent Withdrawal Symptoms Associated with Benzodiazepine Use and Discontinuation	506
1. Daytime Anxiety, Early Morning Insomnia and Other Hyperexcitability Phenomena During Drug Administration	507
2. Rebound Insomnia and Anxiety Following Drug Withdrawal	509
II. Less Frequent but Severe Withdrawal Phenomena Following Benzodiazepine Discontinuation	512
D. Risk Factors Associated with Benzodiazepine Dependence	512
I. Dose	512
II. Duration of Drug Administration	514
III. Gradual Versus Abrupt Discontinuation	515
IV. Benzodiazepine Dependence and Patient Type	516
1. Subjects with Substance Abuse Disorders	516
2. Subjects with Psychiatric Disorders	517
3. Subjects with Sleep Disorders	517
E. Pharmacological Properties Associated with Benzodiazepine Dependence	518
I. Absorption Rate	518
II. Elimination Rate	518

III. Receptor-Binding Affinity 519

IV. Benzodiazepine Effects on the LC-NE and HPA Axes 520

 1. Tolerance, Daytime Anxiety
 and Other Hyperexcitability Phenomena
 During Drug Administration 522

 2. Withdrawal Difficulties (Rebound Insomnia
 and Anxiety and Seizures) 523

V. Role of Other Neurotransmitters
 in Benzodiazepine Dependence 524

VI. Conclusions 524

F. Summary 525

References 526

CHAPTER 20

Sleep Disturbances as Side Effects of Therapeutic Drugs

A. KALES and A.N. VGONTZAS 537

A. Factors Contributing to a Drug's Capacity
 to Induce Sleep Disturbances 537

B. Insomnia 540

 I. Stimulants 540

 II. Stimulant Antidepressants 541

 III. Hypnotics and Anxiolytics 541

 1. Drug Withdrawal Insomnia 541

 2. Early Morning Insomnia and Daytime Anxiety 542

 3. Rebound Insomnia and Rebound Anxiety 542

 4. Sleep Disturbances with Newer Anxiolytics 543

 IV. Corticosteroids 543

 V. Bronchodilators 543

 VI. Antihypertensives 544

 VII. Other Drugs 544

C. Excessive Daytime Sleepiness 545

 I. Hypnotics and Anxiolytics 545

 II. Sedative Neuroleptics 546

 III. Sedative Antidepressants 546

 IV. Anticonvulsants 547

 V. Antihistamines 547

D. Sleep Apnea 548

 I. CNS Depressants 548

 1. Hypnotics 548

 2. Narcotics 549

 3. Anesthetics 549

 II. Antihypertensives 550

III. Testosterone	550
IV. Other Drugs	551
E. Nocturnal Myoclonus	551
F. Auxiliary Symptoms of Narcolepsy	551
G. Somnambulism/Night Terrors	552
I. Lithium	552
II. Hypnotics	552
III. Other Drugs	553
H. REM Behavior Disorder	553
I. Nightmares	554
I. Antihypertensives	554
II. Psychotropic Drugs	554
III. Other Drugs	555
J. Circadian Rhythm Disorders	555
K. Summary	555
References	557
 Subject Index	 569